| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.094 | 0.02 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | 0.28 | 0.02 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.02 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.072 | 0.02 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |